Oral Treosulfan as Second-Line Treatment in Platinum-Resistant Ovarian Cancer: A Phase II Study

Author： Keldsen N.   Madsen E.L.   Havsteen H.   Kamby C.   Laursen L.   Sandberg E.   on behalf of The Danish Ovarian Cancer Study Group  

Publisher： Elsevier

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.69, Iss.2, 1998-05, pp. : 100-102

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Platinum-Resistant and Refractory Ovarian Cancer: Second-Line Treatment Options

By Alvarez A.A.   Clarke-Pearson D.L.  

American Journal of Cancer, Vol. 2, Iss. 1, 2003-01 ,pp. : 1-13

Adis International

Access to resources Recommend Favorite

Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma

By Sorensen P.   Hoyer M.   Jakobsen A.   Malmstrom H.   Havsteen H.   Bertelsen K.  

Gynecologic Oncology, Vol. 81, Iss. 1, 2001-04 ,pp. : 58-62

Elsevier

Access to resources Recommend Favorite

Treosulfan as an Effective Second-Line Therapy in Ovarian Cancer

By Gropp M.   Meier W.   Hepp H.  

Gynecologic Oncology, Vol. 71, Iss. 1, 1998-10 ,pp. : 94-98

Elsevier

Access to resources Recommend Favorite

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

By Manetta A.   Blessing J.A.   Hurteau J.A.  

Gynecologic Oncology, Vol. 68, Iss. 1, 1998-01 ,pp. : 45-46

Elsevier

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Garcia Agustin  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 45-46

Informa Healthcare

Access to resources Recommend Favorite